Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 pos TP53 R248Q |
Therapy | YX-02-030 |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 pos TP53 R248Q | triple-receptor negative breast cancer | sensitive | YX-02-030 | Preclinical - Patient cell culture | Actionable | In a preclinical study, YX-02-030 decreased survival in a triple-negative breast cancer (TNBC) cell line harboring TP53 R248Q in culture, decreased Mdm2 expression and increased apoptosis in patient-derived TNBC explants in culture, and increased apoptosis and decreased survival in 3D mammosphere cultures (PMID: 36734633). | 36734633 |
PubMed Id | Reference Title | Details |
---|---|---|
(36734633) | Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. | Full reference... |